Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers

Overview

This study aims to evaluate the influence of tegoprazan or RAPA114 on the Pharmacokinetic characteristics of atorvastatin following co-administration of tegoprazan or RAPA114 in healthy adult volunteers.

Full Title of Study: “An Open-label, Randomized, Multiple-dose, Replicated Crossover Study to Evaluate Drug-drug Interaction Following Co-administration of Tegoprazan or RAPA114 With Atorvastatin in Healthy Adults”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 12, 2020

Detailed Description

[Pharmacokinetic Assessments] : Blood concentration of atorvastatin, 2-OH atorvastatin – Primary outcome: AUCτ, Css,max of atorvastatin – Secondary outcome: Tss,max of atorvastatin, AUCτ, Css,max of 2-OH atorvastatin, metabolic ratio [Sefety Assessments] : Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test

Interventions

  • Drug: Atorvastatin 40 mg
    • Atorvastatin 40 mg
  • Drug: Tegoprazan 50 mg
    • Tegoprazan 50 mg tablet
  • Drug: RAPA114
    • RAPA114 tablet

Arms, Groups and Cohorts

  • Placebo Comparator: Atorvastatin 40 mg
    • Oral administration of Atorvastatin 40 mg tablet once daily for 7 days
  • Experimental: Atorvastatin 40 mg + Tegoprazan 50 mg
    • Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days
  • Active Comparator: Atorvastatin 40 mg + RAPA114
    • Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days

Clinical Trial Outcome Measures

Primary Measures

  • AUCτ of atorvastatin
    • Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
    • Area under the plasma drug concentration-time curve at steady state
  • Css,max of atorvastatin
    • Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
    • Maximum concentration of drug in plasma of atorvastatin at steady state

Secondary Measures

  • Tss,max of atorvastatin
    • Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
    • Time to Cmax at steady state
  • AUCτ of 2-OH atorvastatin
    • Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
    • Area under the plasma drug concentration-time curve at steady state
  • Css,max of 2-OH atorvastatin
    • Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
    • Maximum concentration of drug in plasma of 2-OH atorvastatin at steady state
  • metabolic ratio
    • Time Frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period
    • AUCτ of 2-OH atorvastatin / AUCτ of atorvastatin

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male adults aged 19 to 55 years (inclusive) at the time of his consent. – Body mass index (BMI) ≥ 19.0 and ≤ 27.0 kg/m2 at screening. – Decides to participate voluntarily in the trial after being fully informed of and understanding the study completely, and provides the written informed consent to participate in the trial and to comply with the trial-specific requirements. – Has the ability and willingness to participate in the entire period of clinical trial. Exclusion Criteria:

  • A subject with clinically significant disease or history of hepatobiliary, renal, gastrointestinal, cardiovascular, musculoskeletal, endocrine, respiratory, neuropsychiatry or hemato-oncologic system, etc. – A subject with a history of hypersensitivity reactions to main constituents of or identical affiliation of the investigational products (ex, HMG-CoA reductase inhibitor, gastric acid suppressants), or have allergic diseases that require treatment. – A subject with a history of genetic myopathy or family history. – A subject who has participated in other clinical trials and received the investigational products within 180 days prior to the randomization. – A subject who received any medications or foods that could significantly affect the absorption, distribution, metabolism, or excretion of an investigational product within 30 days prior to the randomization. – A subject with history of whole blood donation within 60 days, or with blood components or received transfusion within 30 days prior to the randomization. – A subject with continued consumption of alcohol more than 140 g per week. – A subject with AST, ALT, or γ-GT levels exceeding 1.5 times of the upper limit of the reference range in the screening test. – A subject with a calculated glomerular filtration rate of less than 60 mL / min / 1.73 m2 in the screening test. – A subject with any positive result on serology tests for hepatitis B, hepatitis C, HIV or syphilis in the screening test. – A subject with galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose malabsorption, etc. – Male subject who don't have willing to accept medically acceptable contraceptive methods during the course of clinical trial, or who plan to provide sperm. – A subject who is determined to be ineligible to participate in the clinical trial by the investigator for other reasons.

Gender Eligibility: Male

Minimum Age: 19 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • HK inno.N Corporation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jung-ryul Kim, Principal Investigator, Samsung Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.